Immuron (original) (raw)
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is primarily focused on antigen-primed as well as dairy-derived health products. Its proprietary technologies allow a rapid development for polyclonal antibody and other proteins-based solutions to a range of important diseases.. The company specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Anthrax containment.
| Property | Value |
|---|---|
| dbo:abstract | Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is primarily focused on antigen-primed as well as dairy-derived health products. Its proprietary technologies allow a rapid development for polyclonal antibody and other proteins-based solutions to a range of important diseases.. The company specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. (en) |
| dbo:wikiPageExternalLink | http://www.immuron.com.au |
| dbo:wikiPageID | 10853453 (xsd:integer) |
| dbo:wikiPageLength | 2483 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1086682848 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Antigen dbr:Melbourne dbr:Anthrax dbr:Australia dbr:Irritable_bowel_syndrome dbc:Pharmaceutical_companies_of_Australia dbr:Escherichia_coli dbr:Mucositis dbc:Companies_listed_on_the_Australian_Securities_Exchange dbr:Biotechnology dbr:Avian_influenza dbr:Inflammatory_bowel_disease dbr:Travellers'_diarrhoea |
| dbp:wikiPageUsesTemplate | dbt:Advert dbt:Citation_needed dbt:Multiple_issues dbt:Notability dbt:Refimprove dbt:Use_Australian_English dbt:Use_dmy_dates dbt:Pharmacy-stub dbt:Biotech-stub |
| dcterms:subject | dbc:Pharmaceutical_companies_of_Australia dbc:Companies_listed_on_the_Australian_Securities_Exchange |
| rdfs:comment | Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is primarily focused on antigen-primed as well as dairy-derived health products. Its proprietary technologies allow a rapid development for polyclonal antibody and other proteins-based solutions to a range of important diseases.. The company specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Anthrax containment. (en) |
| rdfs:label | Immuron (en) |
| owl:sameAs | wikidata:Immuron https://global.dbpedia.org/id/4Q1qV |
| prov:wasDerivedFrom | wikipedia-en:Immuron?oldid=1086682848&ns=0 |
| foaf:homepage | http://www.immuron.com.au |
| foaf:isPrimaryTopicOf | wikipedia-en:Immuron |
| is dbo:wikiPageRedirects of | dbr:Anadis |
| is dbo:wikiPageWikiLink of | dbr:Anadis |
| is foaf:primaryTopic of | wikipedia-en:Immuron |